Literature DB >> 27686969

First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner is….

O Juan1, N Yousaf2, S Popat3.   

Abstract

Entities:  

Year:  2016        PMID： 27686969     DOI： 10.1016/j.clon.2016.09.007

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN： 0936-6555            Impact factor:   4.126


× No keyword cloud information.
  3 in total

Review 1.  Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy.

Authors:  Qamar Ghafoor; Shobhit Baijal; Phillipe Taniere; Brendan O'Sullivan; Matthew Evans; Gary Middleton
Journal:  Pathol Oncol Res       Date:  2017-12-21       Impact factor: 3.201

2.  Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.

Authors:  Keita Masuzawa; Hiroyuki Yasuda; Junko Hamamoto; Shigenari Nukaga; Toshiyuki Hirano; Ichiro Kawada; Katsuhiko Naoki; Kenzo Soejima; Tomoko Betsuyaku
Journal:  Oncotarget       Date:  2017-11-06

3.  Predictive biomarkers in nonsmall cell carcinoma and their clinico-pathological association.

Authors:  Anurag Mehta; Nayana N Sriramanakoppa; Poojan Agarwal; Gayatri Viswakarma; Smreti Vasudevan; Manoj Panigrahi; Dushyant Kumar; Mumtaz Saifi; Irfan Chowdhary; D C Doval; Moushumi Suryavanshi
Journal:  South Asian J Cancer       Date:  2019 Oct-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.